Format

Send to

Choose Destination
Electron Physician. 2018 Feb 25;10(2):6279-6285. doi: 10.19082/6279. eCollection 2018 Feb.

Prophylactic effect of riboflavin on pediatric migraine: a randomized, double-blind, placebo-controlled trial.

Author information

1
M.D., Pediatric Neurologist, Professor, Department of Pediatrics, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
2
Infectious Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran.
3
M.D., Pediatric Infectious Diseases specialist, Associate Professor, Department of Pediatrics, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
4
Ph.D. of Pharmacology, Associate Professor, Department of Pharmacology, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
5
M.Sc. of biostatistics, Lecturer, Department of Public Health, Faculty of Health, Kashan University of Medical Sciences, Kashan, Iran.
6
M.D., Student Research Committee, Tehran University of Medical Sciences, Tehran, Iran.
7
M.D., Forensic Medicine Specialist, Assistant Professor, Department of Forensic Medicine, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Abstract

Background and aim:

Riboflavin may have an acceptable effect on migraine among children. This study was carried out to determine the prophylactic effect of riboflavin on migraine in children.

Methods:

This randomized clinical trial study was performed at Shahid Beheshti Hospital in Kashan, Iran from December 2012 to February 2015. Ninety children with migraine were allocated randomly into 3 groups (placebo, low-dose and high-dose riboflavin). The outcomes (frequency, intensity and duration of headaches) were measured at baseline and 12 weeks of medication in each group, and the decrease of them were compared. SPSS software version 16 was used for analysis of the data. Descriptive statistics, Chi-square, Fisher's exact and t-test were used for statistical analyses.

Results:

There was a significant decrease of migraine frequency (p=0.000) and mean duration (p=0.000) in the high-dose group compared with the placebo group. No significant reduction of frequency and mean duration of attacks were reported in the low-dose group compared to the placebo group (p=0.49 and p=0.69 respectively). There was no significant reduction of migraine intensity in the low-dose and high-dose groups compared to the placebo group (p=0.71 and p=0.74 respectively).

Conclusion:

High-dose riboflavin is a safe, well tolerated, cost-effective method of prophylaxis for children with migraine.

Trial registration:

The trial was registered at the Iranian Clinical Trial Registry with number IRCT2013020412361N1.

Funding:

The study was supported by the Deputy of Research, Kashan University of Medical Sciences (grant number 91073).

KEYWORDS:

Children; Migraine; Prophylaxis; Riboflavin

Conflict of interest statement

Conflict of Interest: There is no conflict of interest to be declared.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center